Vedder Thinking | Events The Myriad of Possibilities: Implications of the Supreme Court's Myriad Decision
July 10, 2013
10:00 AM - 11:30 AM Eastern Standard Time
Join members from the Vedder Price Intellectual Property group for a complimentary 90-minute webinar.
In Association for Molecular Pathology v. Myriad Genetics, the U.S. Supreme Court unanimously held that naturally occurring DNA is a product of nature and, even if isolated, is not patent eligible. The High Court cautioned that its decision had limitations; for instance, synthetically created complementary DNA (cDNA) is patentable. But between and around those contours, the decision leaves many questions, and its impact on the biotechnology industry is considerable and far-reaching.
Topics to be discussed include:
- What the decision means to issued patent claims
- Patent-eligible claims involving genetic material
- Dovetailing Myriad with Mayo Collaborative Services v. Prometheus, Inc.
- Extrapolation to other naturally occurring biological products
- Other possible contentions in Myriad that were not addressed by the Supreme Court
Vedder Price is an Accredited Continuing Legal Education Provider in Illinois and New York. Assuming minimum CLE requirements are met, this program will offer 1.5 hours of Illinois CLE Credit and 1.5 hours of New York CLE Credit.